# NRG-BR002: metastasis-directed ablation during first-line therapy for limited metastatic breast cancer

Source: https://onco.cc/key-papers/paper-nrg-br002-jco-2026/  
OnCo record `paper-nrg-br002-jco-2026` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

NRG-BR002 did not show improved progression-free or overall survival from adding metastasis-directed ablation in its selected breast-cancer population. This result is distinct from local palliation.

## Summary

Randomised phase 2/3 design in breast cancer with no more than four metastases, a controlled primary and no progression during up to twelve months of first-line systemic treatment. All visible metastases had to be amenable to SBRT or surgery. The 2026 report enrolled 129 patients and analysed 125 eligible participants; 79 percent had HR-positive, HER2-negative disease. Ablation was SBRT in 93 percent.

With median follow-up 29.9 months and 72 progression events, the study did not meet the progression endpoint needed to proceed to phase 3. Its outcome does not establish that ablation is incapable of local control or symptom relief, or answer every breast subtype, later therapy or metastatic setting.

## Fields

- Kind: Key paper
- Last checked: 2026-11-09
- Tags: education-audit; local-treatment
- Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- Year: 2026
- DOI: 10.1200/jco-26-00201
- Authors: Chmura SJ, Winter KA, Woodward WA, Borges VF, Salama JK, Al-Hallaq HA, Matuszak MM, Milano MT, Jaskowiak NT, Jagsi R, Kuhn P, Lucci A, Meas S, Shishido SN, Mason J, Bazan JG, Nordal RA, Lee DY, Smith BD, Gabos Z, Ye JC, Kahn ST, Vallow LA, Zoberi I, Razaq W, Mishra MV, Lupinacci KM, Moughan J, Mamounas EP, White JR.
- Findings: Median progression-free survival: 23.0 months without ablation versus 19.5 with it; hazard ratio 0.92, 95 percent confidence interval 0.57 to 1.47.; The report gives one-sided p=0.36 and stratified p=0.42 for progression. These are different reported analyses, not a value to silently interchange.; Overall-survival hazard ratio 1.07, 95 percent confidence interval 0.60 to 1.89; no statistically significant difference was shown.; No grade 5 toxicity was reported; this does not mean no lower-grade harms occurred.
- What it means: Demonstrates why a local-treatment name and a small number of metastases do not establish added patient-level benefit. Preserve the studied population, systemic strategy and endpoint.
- Caveats: Most participants had HR-positive, HER2-negative cancer; the result does not independently settle every TNBC subgroup.; The trial did not proceed to phase 3. A planned phase 2/3 label is not evidence that the phase 3 portion was completed.; Exploratory circulating-tumour-cell findings do not establish a validated local-ablation selection rule.; The authors advise against routine use outside trials except palliation in this studied setting. The comparison does not erase the distinct symptom-relief question.

## Sources

- Primary publication identity and abstract: https://pubmed.ncbi.nlm.nih.gov/42842849/
- Full original report and analysis context: https://pmc.ncbi.nlm.nih.gov/articles/PMC13647293/
- NRG-BR002 registry: https://clinicaltrials.gov/study/NCT02364557

## Connected records

- terms: [Systemic versus local therapy](https://onco.cc/terms/systemic-vs-local-therapy/)
- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/)
- technologies: [SBRT / SABR (stereotactic radiotherapy)](https://onco.cc/technologies/sbrt/)
- trials: [NRG-BR002: metastasis-directed ablation in limited metastatic breast cancer](https://onco.cc/trials/nrg-br002/)

---
JSON: https://onco.cc/api/v1/entities/paper-nrg-br002-jco-2026.json